Accuray wins Japanese regulatory nod for Radixact platform

Accuray (NSDQ:ARAY) said today it won approval from the Japanese Ministry of Health, Labor and Welfare for its Radixact treatment delivery platform designed for image-guided radiotherapy treatments designed for cancer patients. Clearances include the Radixact treatment delivery system, Accuray Precision treatment planning system and iDMS data management system, the Sunnyvale, Calif.-based company said. “The approval of the Radixact System represents a key milestone in our strategic growth plans for the Japanese market. We are seeing positive momentum in the adoption of the Radixact System as clinicians become aware of its benefits. Feedback from a number of early customers indicates the System enables them to deliver precise radiation therapy, to more patients, in considerably less time than has been possible with the TomoTherapy System,” prez & CEO Joshua Levine said in a prepared statement. The newly cleared system features a more powerful linear accelerator, MVCT imaging and helical treatment delivery designed for the application of conformal and homogenous dose distributions. The system also includes smart, automated workflows and midcourse decision making tools to allow for adaptation to changes in tumor size, shape and location within the patient. “The Accuray team strives to provide our customers with innovative products that enhance the quality of patient care. With the introduction of the Radixact System, we are demonstrating significant progr...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Oncology Regulatory/Compliance Accuray Inc. Source Type: news